Glucose and lipid metabolism and insulin sensitivity in type 1 diabetes: the effect of guar gum

1988 ◽  
Vol 48 (1) ◽  
pp. 98-103 ◽  
Author(s):  
P Ebeling ◽  
H Yki-Järvinen ◽  
A Aro ◽  
E Helve ◽  
M Sinisalo ◽  
...  
Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 921-P
Author(s):  
MICHELLE A. VAN NAME ◽  
STEPHAN SIEBEL ◽  
EILEEN M. TICHY ◽  
SONIA CAPRIO ◽  
WILLIAM V. TAMBORLANE ◽  
...  

Author(s):  
Veranika Prylutskaya ◽  
Anzhalika Solntsava ◽  
Antonina Goncharik ◽  
Marya Pavlovets ◽  
Ivan Kurlovich

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1054-P
Author(s):  
MICHELE SCHIAVON ◽  
ALFONSO GALDERISI ◽  
KRISTEN A. KRAEMER ◽  
CLAUDIO COBELLI ◽  
CHIARA DALLA MAN ◽  
...  

2021 ◽  
Vol 9 (5) ◽  
Author(s):  
William E. Novotny ◽  
Irma Fiordalisi ◽  
Cynthia P. Keel ◽  
Glenn D. Harris

2006 ◽  
Vol 91 (11) ◽  
pp. 4287-4294 ◽  
Author(s):  
Tania S. Burgert ◽  
Sara E. Taksali ◽  
James Dziura ◽  
T. Robin Goodman ◽  
Catherine W. Yeckel ◽  
...  

Abstract Background: Concurrent with the rise in obesity, nonalcoholic fatty liver disease is recognized as the leading cause of serum aminotransferase elevations in obese youth. Nevertheless, the complete metabolic phenotype associated with abnormalities in biomarkers of liver injury and intrahepatic fat accumulation remains to be established. Methods: In a multiethnic cohort of 392 obese adolescents, alanine aminotransferase (ALT) levels were related with parameters of insulin sensitivity, glucose, and lipid metabolism as well as adipocytokines and biomarkers of inflammation. A subset of 72 adolescents had determination of abdominal fat partitioning and intrahepatic fat accumulation using magnetic resonance imaging. Findings: Elevated ALT (>35 U/liter) was found in 14% of adolescents, with a predominance of male gender and white/Hispanic race/ethnicity. After adjusting for potential confounders, rising ALT was associated with reduced insulin sensitivity and glucose tolerance as well as rising free fatty acids and triglycerides. Worsening of glucose and lipid metabolism was already evident as ALT levels rose into the upper half of the normal range (18–35 U/liter). When hepatic fat fraction was assessed using fast magnetic resonance imaging, 32% of subjects had an increased hepatic fat fraction, which was associated with decreased insulin sensitivity and adiponectin, and increased triglycerides, visceral fat, and deep to superficial sc fat ratio. The prevalence of the metabolic syndrome was significantly greater in those with fatty liver. Interpretation: Deterioration in glucose and lipid metabolism is associated even with modest ALT elevations. Hepatic fat accumulation in childhood obesity is strongly associated with the triad of insulin resistance, increased visceral fat, and hypoadiponectinemia. Hence, hepatic steatosis may be a core feature of the metabolic syndrome.


2020 ◽  
Vol 46 (1) ◽  
pp. 75-77
Author(s):  
Beata Mianowska ◽  
Iwona Pietrzak ◽  
Małgorzata Perenc ◽  
Anna Baranowska-Jaźwiecka ◽  
Wojciech Fendler ◽  
...  

2014 ◽  
Vol 28 (3) ◽  
pp. 298-304 ◽  
Author(s):  
Petter Bjornstad ◽  
Janet K. Snell-Bergeon ◽  
Kimberly McFann ◽  
R. Paul Wadwa ◽  
Marian Rewers ◽  
...  

Diabetes Care ◽  
2014 ◽  
Vol 37 (10) ◽  
pp. e219-e220
Author(s):  
Gayatri Sarkar ◽  
May Alattar ◽  
Rebecca J. Brown ◽  
Michael J. Quon ◽  
David M. Harlan ◽  
...  

1992 ◽  
Vol 127 (4) ◽  
pp. 344-350 ◽  
Author(s):  
Allan A Vaag ◽  
Henning Beck-Nielsen

The effect of prolonged treatment with Acipimox on in vivo peripheral insulin sensitivity, and on glucose and lipid metabolism, was investigated in patients with NIDDM in a double-blind study. Twelve NIDDM patients were randomized to treatment with either placebo or Acipimox in pharmacological doses (250 mg×3) for three months. Fasting plasma glucose, insulin, C-peptide and HbA1c concentrations were unaffected after three months of acipimox treatment. However, fasting plasma non-esterifled fatty acid (NEFA) concentrations were twofold elevated after Acipimox treatment (1.34±0.09 vs 0.66±0.09 mmol/l; p<0.05). Despite this, repeated acute Acipimox administration after the three months' treatment period enhanced total insulin-stimulated glucose disposal to the same extent as acute Acipimox administration before the treatment period (367±59 vs 392±66 mg·m−2·min−1, NS; both p<0.05 vs placebo glucose disposal) (267±44 mg·m−2·min−1). In conclusion, insulin resistance or tachyphylaxis towards the effects of Acipimox on insulin stimulated glucose disposal was not induced during prolonged Acipimox treatment. The lack of improvement of blood glucose control in the patients with NIDDM may be due to the demonstrated rebound effect of lipolysis.


Sign in / Sign up

Export Citation Format

Share Document